Ref (type)	Population	Outcome, Interventions	Results and statistical analysis	Effect size	Favours
Vascular event
RCT	6748 people with peripheral arterial disease Subgroup analysis	Proportion of people with a first major vascular event (major coronary event, stroke, and revascularisation) 895 (26%) with simvastatin 40 mg daily 1101 (33%) with placebo Absolute numbers not reported	Absolute reduction of 63 per 1000 P <0.001	Effect size not calculated	Simvastatin 40 mg daily
RCT	2701 people with peripheral arterial disease but without diagnosed CHD Subgroup analysis	Proportion of people with a first major vascular event (major coronary event, stroke, and revascularisation) 327/1325 (25%) with simvastatin 40 mg daily 420/1376 (31%) with placebo	P <0.0001	Effect size not calculated	Simvastatin 40 mg daily
RCT	5804 people; aged 70 to 82 years; 513 (9%) with intermittent claudication or previous peripheral arterial surgery	Proportion of people with a non-fatal MI, fatal or non-fatal stroke, or coronary death mean follow-up of 3.2 years 408/2891 (14%) with pravastatin 40 mg daily 473/2913 (16%) with placebo	HR 0.85 95% CI 0.74 to 0.97	Small effect size	Pravastatin 40 mg daily
RCT	10,305 people with hypertension; 514 (5%) with peripheral arterial disease	Proportion of people with a cardiovascular event (non-fatal MI and fatal CHD) median follow-up of 3.3 years 389/5168 (8%) with atorvastatin 10 mg daily 486/5137 (9%) with placebo	HR 0.79 95% CI 0.69 to 0.90	Small effect size	Atorvastatin 10 mg daily
RCT	10,305 people with hypertension; 514 (5%) with peripheral arterial disease	Proportion of people with a coronary event median follow-up of 3.3 years 178/5168 (3%) with atorvastatin 10 mg daily 247/5137 (5%) with placebo	HR 0.71 95% CI 0.59 to 0.86	Small effect size	Atorvastatin 10 mg daily
RCT	10,305 people with hypertension; 514 (5%) with peripheral arterial disease	Proportion of people with a fatal or non-fatal stroke median follow-up of 3.3 years 89/5168 (1.7%) with atorvastatin 10 mg daily 121/5137 (2.4%) with placebo	HR 0.73 95% CI 0.56 to 0.96	Small effect size	Atorvastatin 10 mg daily
RCT 3-armed trial	354 people with peripheral arterial disease and intermittent claudication In review	Proportion of people with a cardiovascular event (MI and stroke) 3/120 (2.5%) with atorvastatin 80 mg daily 3/114 (2.6%) with placebo	Significance not assessed
RCT 3-armed trial	354 people with peripheral arterial disease and intermittent claudication In review	Proportion of people with a cardiovascular event (MI and stroke) 5/120 (4%) with atorvastatin 10 mg daily 3/114 (3%) with placebo	Significance not assessed